BACKGROUND AND OBJECTIVES: We analyzed in a retrospective analysis whether adjuvant chemotherapy with mitomycin (MMC) alone or with Tegafur (TG) is associated with long-term survival benefit in resected gastric cancer. Other prognostic factors are compared. METHODS: From 1977 to 1998, 314 consecutive totally resected gastric adenocarcinoma patients have been included in a survival study. In 151 patients no adjuvant therapy was given. In 163 patients, four courses of adjuvant chemotherapy was given, 109 of them with MMC, 10-20 mg/m(2) i.v. every 6 weeks and the other 54 with MMC plus TG, 500 mg/m(2) p.o. day for 42 consecutive days. Univariate and multivariate survival analyses were performed. RESULTS: Survival benefit was seen in patients who had received adjuvant chemotherapy compared with the controls (52% vs. 30% alive at the end of the study, relative risk = 0.46, 95% CI: 0.33-0.62, P < 0.0001), women (52% vs. 35%, RR = 0.83, 95% CI: 0.71-0.98, P = 0.0342) and increment of staging IB, II, IIIA, or IIIB (80, 56, 24 vs. 13%, respectively, RR = 1.83, 95% CI: 1.42-2.35, P < 0.0001). Better prognosis of node-negative patients was observed only in univariate analysis. CONCLUSIONS: After curative surgery, adjuvant chemotherapy with mitomycin C, both alone or combined with Tegafur, improved the long-term cure rate over no postoperative chemotherapy in locally advanced gastric cancer patients. This benefit was not influenced by other prognostic factors. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: We analyzed in a retrospective analysis whether adjuvant chemotherapy with mitomycin (MMC) alone or with Tegafur (TG) is associated with long-term survival benefit in resected gastric cancer. Other prognostic factors are compared. METHODS: From 1977 to 1998, 314 consecutive totally resected gastric adenocarcinomapatients have been included in a survival study. In 151 patients no adjuvant therapy was given. In 163 patients, four courses of adjuvant chemotherapy was given, 109 of them with MMC, 10-20 mg/m(2) i.v. every 6 weeks and the other 54 with MMC plus TG, 500 mg/m(2) p.o. day for 42 consecutive days. Univariate and multivariate survival analyses were performed. RESULTS: Survival benefit was seen in patients who had received adjuvant chemotherapy compared with the controls (52% vs. 30% alive at the end of the study, relative risk = 0.46, 95% CI: 0.33-0.62, P < 0.0001), women (52% vs. 35%, RR = 0.83, 95% CI: 0.71-0.98, P = 0.0342) and increment of staging IB, II, IIIA, or IIIB (80, 56, 24 vs. 13%, respectively, RR = 1.83, 95% CI: 1.42-2.35, P < 0.0001). Better prognosis of node-negative patients was observed only in univariate analysis. CONCLUSIONS: After curative surgery, adjuvant chemotherapy with mitomycin C, both alone or combined with Tegafur, improved the long-term cure rate over no postoperative chemotherapy in locally advanced gastric cancerpatients. This benefit was not influenced by other prognostic factors. Copyright 2003 Wiley-Liss, Inc.
Authors: Ann Driessen; Willy Landuyt; Sylvia Pastorekova; Johnny Moons; Laurence Goethals; Karin Haustermans; Philippe Nafteux; Freddy Penninckx; Karel Geboes; Toni Lerut; Nadine Ectors Journal: Ann Surg Date: 2006-03 Impact factor: 12.969
Authors: Juan J Grau; Ramon Palmero; Maribel Marmol; Jose Domingo-Domenech; Mariano Monzo; Jose Fuster; Oscar Vidal; Constantino Fondevila; Juan C Garcia-Valdecasas Journal: World J Surg Oncol Date: 2006-08-11 Impact factor: 2.754
Authors: Rebecca Zhu; Fangfang Liu; Gabriella Grisotti; Javier Perez-Irizarry; Ronald R Salem; Charles H Cha; Kimberly L Johung; Daniel J Boffa; Yawei Zhang; Sajid A Khan Journal: J Gastrointest Oncol Date: 2018-06
Authors: Joseph Cowling; Bethany Gorman; Afrah Riaz; James R Bundred; Sivesh K Kamarajah; Richard P T Evans; Pritam Singh; Ewen A Griffiths Journal: J Gastrointest Cancer Date: 2020-09-22